XNASECOR
Market cap104mUSD
Jan 17, Last price
15.90USD
1D
1.27%
1Q
97.76%
IPO
-14.52%
Name
electroCore, Inc.
Chart & Performance
P/E
—
P/S
6.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.10%
Rev. gr., 5y
74.42%
Revenues
16m
+86.57%
Net income
-19m
L-15.02%
CFO
-15m
L-11.88%
Earnings
Mar 11, 2025
Profile
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 16,030 86.57% | 8,592 57.62% | ||||||
Cost of revenue | 8,125 | 7,136 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 7,905 | 1,456 | ||||||
NOPBT Margin | 49.31% | 16.95% | ||||||
Operating Taxes | (186) | (431) | ||||||
Tax Rate | ||||||||
NOPAT | 8,091 | 1,887 | ||||||
Net income | (18,834) -15.02% | (22,162) 28.71% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 8,144 | |||||||
BB yield | -24.81% | |||||||
| Debt | ||||||||
Debt current | 178 | 74 | ||||||
Long-term debt | 1,700 | 1,324 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | (537) | (306) | ||||||
Net debt | (8,453) | (15,234) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (14,668) | (16,645) | ||||||
CAPEX | (206) | |||||||
Cash from investing activities | (206) | |||||||
Cash from financing activities | 7,487 | |||||||
FCF | 8,000 | 2,032 | ||||||
| Balance | ||||||||
Cash | 10,331 | 17,712 | ||||||
Long term investments | (1,080) | |||||||
Excess cash | 9,530 | 16,202 | ||||||
Stockholders' equity | (165,262) | (146,434) | ||||||
Invested Capital | 173,419 | 163,780 | ||||||
ROIC | 4.80% | 1.16% | ||||||
ROCE | 96.91% | 8.25% | ||||||
| EV | ||||||||
Common stock shares outstanding | 5,515 | 4,729 | ||||||
Price | 5.95 2,218.17% | 0.26 -55.92% | ||||||
Market cap | 32,825 2,603.48% | 1,214 -47.17% | ||||||
EV | 24,372 | (14,020) | ||||||
EBITDA | 8,930 | 2,004 | ||||||
EV/EBITDA | 2.73 | |||||||
Interest | 287 | |||||||
Interest/NOPBT | 19.71% | |||||||